Screening method of tumor neoantigen

Tumor-specific mutations were screened through whole exome and transcriptome sequencing, combined with bioinformatics tools to predict MHC affinity, screen and verify tumor neoantigens, solving the problem of low efficiency of tumor neoantigen screening in the existing technology and improving tumor The efficacy of immunotherapy can effectively kill tumor cells especially when MHC expression is low.

CN119049554APending Publication Date: 2024-11-29ZHEJIANG CHUANEN CULTURE CO LTD
View PDF 0 Cites 6 Cited by

Patent Information

Application Number
CN202411232957.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art is difficult to effectively screen out efficient tumor neoantigens in tumor immunotherapy, resulting in limited efficacy and traditional methods have poor therapeutic effects on tumors with low MHC expression.

Method used

Tumor-specific mutations were screened through whole-exome sequencing and transcriptome sequencing, combined with bioinformatics tools to predict affinity with MHC molecules, screen out candidate neoantigens with high affinity, and verify their immunogenicity through in vitro experiments. Finally, Verified neoantigens are used in tumor immunotherapy regimens.

Benefits of technology

It has achieved efficient screening and verification of tumor neoantigens, improved the efficacy of tumor immunotherapy, and can effectively play a role in the case of low MHC expression, and enhanced the killing ability of tumor cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119049554A_ABST
    Figure CN119049554A_ABST
Patent Text Reader

Abstract

The invention discloses a method for screening tumor neoantigens, and relates to the technical field of tumor neoantigens, and the method comprises the following steps: carrying out whole exome sequencing on tumor tissues and paired para-carcinoma tissues, carrying out DNA comparison on sequencing results, screening out tumor specific mutation, and verifying mutation sites by using transcriptome sequencing; on the basis, HA genotyping is carried out on peripheral blood cells of tumor patients, and by integrating domestic and overseas related researches on new antigen screening and immunogenicity improvement, large-scale clinical promotion and application of the new antigens still need in-depth researches, so that the screening process is simplified, and the efficient tumor new antigens are identified; the modification of the immunogenicity of the new antigen still focuses on the improvement of the affinity and the stability of a TCR-HLA-peptide compound, other factors possibly influencing the immune effect are positively researched and explored, and the safety and the effectiveness of the new antigen are evaluated based on the results of in-vivo and in-vitro experiments and clinical researches.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of neo-tumor antigens, and specifically to a method for screening neo-tumor antigens. Background Art

[0002] Malignant tumors seriously threaten human life and health. Their mortality rate ranks second among all kinds of diseases, and there is an upward trend. Humans have experienced a long process of understanding and studying tumors, but the efficacy of the widely used traditional treatment methods is still very limited, and tumors cannot be cured fundamentally. With the rapid development of science and technology, studying the mechanism of tumor occurrence and development and early diagnosis and treatment of tumors at the molecular level has become a research hotspot for conquering tumors. Tumor antigens are gene expression products of tumor cells that are different from normal cells. They can effectively induce the body's immune response and produce humoral and cellular immune responses against tumor cells. They are the molecular basis of tumor immunotherapy. Since the relevant research on tumor-specific antigens and tumor-associated antigens has been carried out, the discovery of antigens and antigen modification have been inseparable, becoming the two most important problems in antigen peptide-based anti-tumor immunotherapy. Therefore, the present invention proposes a method for screening new tumor antigens. Summary of the invention

[0003] To achieve the above object, the present invention provides the following technical solution: a method for screening tumor neoantigens, comprising the following steps: S1: Sample collection and sequencing: collect tumor tissue and paired normal tissue samples for whole exome sequencing and transcriptome sequencing; S2: Data analysis and prediction: Use bioinformatics tools to analyze sequencing data and predict tumor-specific mutations and their affinity to MHC molecules; S3: Candidate neoantigen screening: Screen high-affinity candidate neoantigens based on the prediction results; S4: Neoantigen validation: Further experimental validation of the identified potential neoantigens to ensure that they are cancer cell specific and can induce immune responses; S5: Clinical application: Use validated neoantigens in the design and implementation of tumor immunotherapy programs.

[0004] Preferably, whole exome sequencing is performed on the tumor tissue and paired adjacent cancer tissue, and then DNA comparison is performed on the sequencing results to screen out tumor-specific mutations, and then transcriptome sequencing is used to verify the mutation sites; on this basis, HA genotyping is performed on peripheral blood cells of tumor patients, and the affinity of antigen peptides at candidate mutation sites to HLA-I is predicted by bioinformatics software such as NetMHCpan, and the antigen peptides with the highest affinity are screened out, and finally the antigen peptides are synthesized, and the immunogenicity of the new antigens is verified in vitro, and the APCs loaded with the new antigens are co-cultured with the patient's T cells in vitro, and T cell activation markers are detected to verify whether the new antigens obtained by screening can effectively activate T cell immune responses.

[0005] Preferably, the protein spectrum-based separation of human leukocyte antigen-binding peptides from the surface of tumor cells is a reliable method for identifying HLA-restricted neoantigens. Advanced mass spectrometry technology is used to directly find mutated peptide ligands from the original tumor tissue of melanoma patients. These peptides are considered to be true neoepitopes that are highly relevant to tumor immunotherapy strategies. Mass spectrometry-based analytical methods are used to characterize unconventional HLA peptide libraries and accurately identify hundreds of shared tumor-specific unconventional HLA peptides. Mass spectrometry technology can identify thousands of atypical peptides, most of which come from sequences outside the protein coding region or are produced by atypical antigen processing, reflecting that the process from gene expression to protein translation and then to proteasome hydrolysis into antigenic peptides requires a long "behind-the-scenes" operation.

[0006] Preferably, the chimeric antigen receptor T cell, CAR-T is similar to TCR-T, and its greatest advantage is that it uses BCR to recognize antigens, and can recognize carbohydrates and glycolipids that are not usually recognized by TCR-T, and does not need to go through the antigen presentation process, nor is it restricted by MHC. It can also work on some tumors with low or no MHC expression. CART can also have an "off-target" phenomenon. When using CAR-T cells targeting tyrosine kinase receptor 2 to treat colon cancer patients, a large number of CART cells appeared in the patient's lungs, leading to cytokine release syndrome and multiple organ failure. The preparation of CAR-T targeting tumor-specific neoantigens can solve the "off-target" problem. Currently, clinical trials of CAR-T targeting new targets of ErbB2, gangliosides, and prostate-specific membrane antigen are also underway.

[0007] Preferably, the residue replacement of the antigen epitope is to replace the residue at the site where the tyrosinase-associated protein 2 antigen epitope located on melanocytes interacts with the HLA-A*0201 molecule. The affinity and stability of the peptide after the replacement are improved, and its ability to stimulate and activate T cells and kill tumor cells are better than the wild-type tyrosinase-associated protein 2 epitope; the study found that the P modification at the third position (p3) of the melanoma-related epitope gp10025-33 directly improves the affinity of the epitope with TCR, and the amino-terminal anchoring site of the antigen peptide binding motif plays a key role in stabilizing the pMHC-I complex. The antigen peptide p2 replaces aspartic acid with tyrosine, or replaces proline / arginine with leucine at the amino terminus to strengthen the conformational stability of the peptide to facilitate MHC binding. The single residue is replaced based on the pi-pi stacking interaction between the residues, especially after p9 is replaced, the immunogenicity of the weak antigen, the binding free energy between the antigen and HLA, and the CTL activation level are improved.

[0008] Preferably, the tumor antigen screening based on specifically reactive CD8+ and CD4+T cells is mainly to transfect the cDNA library of tumor cells into a cell line expressing MHC-I or MHC-Ⅱ molecules, and then co-culture with the established CD8+ or CD4+T cell line that specifically responds to tumor cells, obtain positive cell clones by detecting cell lysis or cytokine release, and finally amplify the positive monoclonal cells to obtain DNA, which is further identified after sequencing. Based on this principle, it has been reported that the screening system for MHC-I and MHC-Ⅱ tumor antigens has been reconstructed and achieved good results. A retrovirus cloning system has been established for MHC-I tumor antigens, in which the tumor cell cDNA library is cloned into a human retrovirus vector, co-transfected with a plasmid encoding VSVG protein into a 293GP packaging cell line, the viral supernatant is collected, and then the autologous fibroblasts are infected. , and then co-cultured with CD8+T cells that have a specific response to tumor cells, and the positive cell clones were determined by detecting the release of T cell factors. The feasibility of this system has been demonstrated by the screening and identification of NY-ESO-1 tumor antigens; for the screening of MHC-Ⅱ tumor antigens, according to the processing principle of MHC-I molecules, cDNAs encoding DRα, DRβ, DMα, DMβ and Ii were transferred to 293 cells, and 293IMDR cells were established. This genetically engineered cell has the same ability to process and present antigens as antigen-presenting cells. Then, a tumor cell cDNA fusion library fused with the Ii targeting sequence was constructed. The combined use of this tumor cell cDNA fusion library and 293IMDR cells made the screening of MHC-Ⅱ tumor antigens relatively simple and quick, which was significantly better than other methods. Tumor antigens such as CDC27 and LDFP were obtained using this screening system.

[0009] Preferably, the immunogenicity of the predicted neoantigen is usually detected by T response. Although the frequency of neoantigen-reactive T cells in peripheral blood is usually lower than that in tumor samples, the neoantigen-specific T cells derived from circulating CD8+ memory T cells of cancer patients or circulating CD8+ naive T cells of healthy volunteers are enriched by in vitro co-culture with homologous DC cells loaded with neoantigens, and their response ability to recognize neoantigens can be detected by conventional experimental methods. The circulating CD8T cells of healthy donors that are more easily obtained are co-cultured with homologous DC loaded with neoantigens for two rounds to verify the immunogenicity of the predicted neoantigens. Except for the positive epitope KRAS_G12V8-16, it was found that 11 of the 25 predicted antigens could induce the co-cultured CTLs to secrete IFN-γ and produce IFN- The frequency of specific CTLs with γ spot numbers exceeding 10 times that of the negative control was between 0.22% and 7.08%. The remaining 14 candidate neoantigens were not found to be immunogenic. It is speculated that this is because only about 1 T cell out of 10E5 to 10E6 T cells in general lymph nodes is a neoantigen-specific T cell, and the circulating CD8+ memory T cells of healthy donors do not produce neoantigen-reactive T cells. Enriching the circulating CD8+ naive T cells of healthy volunteers before antigen sensitization can increase the possibility of specific T cells encountering D presenting relevant neoantigens. Due to the individual differences in donor-dependent T cell populations and sufficient diversity of the human TCR library, multiple donors need to be screened to identify the immunogenicity of candidate neoantigens. The remaining neoantigen peptides with negative immunogenicity may be obtained from the positive CTLs screened from other healthy volunteers.

[0010] Compared with the prior art, the present invention has the following beneficial effects: The present invention summarizes relevant research findings on neoantigen screening and immunogenicity improvement at home and abroad and finds that the large-scale clinical promotion and application of neoantigens still need in-depth research, so as to simplify the screening process and identify highly effective tumor neoantigens. The modification of neoantigen immunogenicity still focuses on improving the affinity and stability of the TCR-HLA-peptide complex, actively studying and exploring other factors that may affect the immune effect, and evaluating its safety and effectiveness based on the results of in vitro and in vivo experiments and clinical studies. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 This is a flowchart for screening new tumor antigens of the present invention. DETAILED DESCRIPTION

[0012] See also Figure 1 The present invention provides a technical solution: a method for screening tumor neoantigens, comprising the following steps: S1: Sample collection and sequencing: collect tumor tissue and paired normal tissue samples for whole exome sequencing and transcriptome sequencing; S2: Data analysis and prediction: Use bioinformatics tools to analyze sequencing data and predict tumor-specific mutations and their affinity to MHC molecules; S3: Candidate neoantigen screening: Screen high-affinity candidate neoantigens based on the prediction results; S4: Neoantigen validation: Further experimental validation of the identified potential neoantigens to ensure that they are cancer cell specific and can induce immune responses; S5: Clinical application: Use validated neoantigens in the design and implementation of tumor immunotherapy programs.

[0013] Whole exome sequencing is performed on tumor tissues and paired adjacent cancer tissues, followed by DNA comparison of the sequencing results to screen out tumor-specific mutations, and then transcriptome sequencing is used to verify the mutation sites. On this basis, HA genotyping is performed on peripheral blood cells of tumor patients, and the affinity of antigen peptides at candidate mutation sites to HLA-I is predicted using bioinformatics software such as NetMHCpan, and the antigen peptides with the highest affinity are screened out. Finally, the antigen peptides are synthesized, and the immunogenicity of the new antigens is verified in vitro. APCs loaded with the new antigens are co-cultured with the patient's T cells in vitro, and T cell activation markers are detected to verify whether the new antigens obtained by screening can effectively activate T cell immune responses. Protein spectrum technology is used to detect the surface of tumor cells. Separation of human leukocyte antigen-bound peptides is a reliable method for identifying HLA-restricted neoantigens. Advanced mass spectrometry technology is used to directly find mutated peptide ligands from the original tumor tissues of melanoma patients. These peptides are considered to be true neoepitopes that are highly relevant to tumor immunotherapy strategies. Mass spectrometry-based analytical methods are used to characterize unconventional HLA peptide libraries and accurately identify hundreds of shared tumor-specific unconventional HLA peptides. Mass spectrometry technology can identify thousands of atypical peptides, most of which come from sequences outside the protein coding region or are produced by atypical antigen processing, which reflects that the process from gene expression to protein translation and then to proteasome enzymatic degradation into antigenic peptides requires a long "behind-the-scenes" operation; Chimeric antigen receptor T cells, CAR-T is similar to TCR-T. Its biggest advantage is that it uses BCR to recognize antigens. It can recognize carbohydrates and glycolipids that are not usually recognized by TCR-T, and does not need to go through the antigen presentation process. It is not restricted by MHC and can also work on some tumors with low or no MHC expression. CART can also have "off-target" phenomena. When using CAR-T cells targeting tyrosine kinase receptor 2 to treat colon cancer patients, a large number of CART cells appeared in the patients' lungs, leading to cytokine release syndrome and multiple organ failure. The preparation of CAR-T targeting tumor-specific new antigens can solve the "off-target" problem. Currently, clinical trials of CAR-T targeting new targets such as ErbB2, gangliosides, and prostate-specific membrane antigen are also underway. The residues of the antigen epitope are replaced, and the tyrosinase-associated protein 2 located on melanocytes is replaced. Residues were replaced at the site where the antigen epitope interacts with the HLA-A*0201 molecule. The affinity and stability of the peptide after the replacement were improved. Its ability to stimulate and activate T cells and kill tumor cells was better than that of the wild-type tyrosinase-related protein 2 epitope. The study found that the P modification at the third position (p3) of the melanoma-related epitope gp10025-33 directly increased the affinity of the epitope with TCR. The amino-terminal anchoring site of the antigen peptide binding motif plays a key role in stabilizing the pMHC-I complex. The antigen peptide p2 replaced aspartic acid with tyrosine, or replaced proline / arginine with leucine at the amino terminus to strengthen the conformational stability of the peptide to facilitate MHC binding. The single residues were replaced based on the pi-pi stacking interaction between the residues, especially after p9 was replaced, the immunogenicity of the weak antigen, the binding free energy between the antigen and HLA, and the CTL activation level were improved. Tumor antigen screening based on specifically reactive CD8+ and CD4+ T cells mainly involves transfecting the cDNA library of tumor cells into a cell line expressing MHC-I or MHC-Ⅱ molecules, which is then co-cultured with the established CD8+ or CD4+ T cell line that specifically responds to tumor cells. Positive cell clones are obtained by detecting cell lysis or cytokine release, and finally positive monoclonal cells are amplified to obtain DNA, which is further identified after sequencing. Based on this principle, there have been reports on the reconstruction of the screening system for MHC-I and MHC-Ⅱ tumor antigens, and good results have been achieved. A reverse transcription disease screening system has been established for MHC-I tumor antigens. The tumor cell cDNA library was cloned into a human retroviral vector and co-transfected with a plasmid encoding VSVG protein into a 293GP packaging cell line. The viral supernatant was collected and infected with the fibroblasts of the patient's own body. The cells were then co-cultured with CD8+T cells that specifically responded to tumor cells, and the positive cell clones were identified by detecting the release of T cell factors. The feasibility of this system was demonstrated by the screening and identification of NY-ESO-1 tumor antigens. For the screening of MHC-Ⅱ tumor antigens, the cDNAs encoding DRα, DRβ, DMα, DMβ and Ii were transferred to 293 cells according to the processing principle of MHC-I molecules, and the 293IMDR cell line was established. The genetically engineered cells have the same ability to process and present antigens as antigen-presenting cells. Then, a tumor cell cDNA fusion library fused with Ii targeting sequence was constructed. The combined application of this tumor cell cDNA fusion library and 293IMDR cells made the screening of MHC-Ⅱ tumor antigens relatively simple and rapid, which was significantly better than other methods. Tumor antigens such as CDC27 and LDFP were obtained using this screening system. The immunogenicity of new antigens is usually predicted by the response of T cells. Although the frequency of new antigen-reactive T cells in peripheral blood is usually lower than that in tumor samples, circulating CD8+ memory T cells from cancer patients or healthy volunteers The neoantigen-specific T cells of circulating CD8+ naive T cells were enriched by co-culture with homologous DC cells loaded with neoantigens in vitro. Their response ability to recognize neoantigens can be detected by conventional experimental methods. The circulating CD8T cells of healthy donors, which are easy to obtain, were co-cultured with homologous DC loaded with neoantigens for two rounds to verify the immunogenicity of the predicted neoantigens. Except for the positive epitope KRAS_G12V8-16, it was found that 11 of the 25 predicted antigens could induce co-cultured CTLs to secrete IFN-Y after loading T2 cells, and the frequency of specific CTLs producing IFN-γ spots that were more than 10 times that of the negative control was between 0.22% and 7.08%, and the remaining 14 candidate neoantigens were not found to be immunogenic. It is speculated that this is because only about 1 T cell out of 10E5-10E6 T cells in the general lymph nodes is a neoantigen-specific T cell, and the circulating CD8+ memory T cells of healthy donors do not produce neoantigen-reactive T cells. Enriching the circulating CD8+ naive T cells of healthy volunteers before antigen sensitization can increase the possibility of specific T cells encountering D presenting relevant neoantigens. Due to the individual differences in donor-dependent T cell populations and the sufficient diversity of the human TCR library, multiple donors need to be screened to identify the immunogenicity of candidate neoantigens. The remaining immunogenic negative neoantigen peptides may be obtained from the positive CTLs screened from other healthy volunteers. .

Claims

1. A method for screening tumor neoantigens, characterized in that: The following steps are involved: S1: Sample collection and sequencing: collect tumor tissue and paired normal tissue samples for whole exome sequencing and transcriptome sequencing; S2: Data analysis and prediction: Use bioinformatics tools to analyze sequencing data and predict tumor-specific mutations and their affinity to MHC molecules; S3: Candidate neoantigen screening: Screen high-affinity candidate neoantigens based on the prediction results; S4: Neoantigen validation: Further experimental validation of the identified potential neoantigens to ensure that they are cancer cell specific and can induce immune responses; S5: Clinical application: Use validated neoantigens in the design and implementation of tumor immunotherapy programs.

2. The method for screening tumor neoantigens according to claim 1, characterized in that: The whole exome sequencing is performed on the tumor tissue and the paired adjacent cancer tissue, and then the sequencing results are compared by DNA to screen out tumor-specific mutations, and then the mutation sites are verified by transcriptome sequencing; on this basis, HA gene typing is performed on the peripheral blood cells of the tumor patient, and the affinity of the antigen peptides at the candidate mutation sites to HLA-I is predicted by bioinformatics software such as NetMHCpan, and the antigen peptides with the highest affinity are screened out, and finally the antigen peptides are synthesized, and the immunogenicity of the new antigens is verified in vitro, and the APCs loaded with the new antigens are co-cultured with the patient's T cells in vitro, and T cell activation markers are detected to verify whether the new antigens obtained by screening can effectively activate T cell immune responses.

3. The method for screening tumor neoantigens according to claim 1, characterized in that: The protein spectrum-based technology for separating human leukocyte antigen-binding peptides from the surface of tumor cells is a reliable method for identifying HLA-restricted neoantigens. Advanced mass spectrometry technology is used to directly find mutated peptide ligands from the original tumor tissues of melanoma patients. These peptides are considered to be true neoepitopes that are highly relevant to tumor immunotherapy strategies. Mass spectrometry-based analytical methods are used to characterize unconventional HLA peptide libraries and accurately identify hundreds of shared tumor-specific unconventional HLA peptides. Mass spectrometry technology can identify thousands of atypical peptides, most of which come from sequences outside the protein coding region or are produced by atypical antigen processing, reflecting that the process from gene expression to protein translation and then to proteasome enzymatic hydrolysis into antigenic peptides requires a long "behind-the-scenes" operation.

4. The method for screening tumor neoantigens according to claim 1, characterized in that: The chimeric antigen receptor T cell, CAR-T is similar to TCR-T. Its biggest advantage is that it uses BCR to recognize antigens. It can recognize carbohydrates and glycolipids that are usually not recognized by TCR-T, and does not need to go through the antigen presentation process. It is not restricted by MHC and can also work on some tumors with low or no MHC expression. CART can also have "off-target" phenomena. When using CAR-T cells targeting tyrosine kinase receptor 2 to treat colon cancer patients, a large number of CART cells appeared in the lungs of patients, leading to cytokine release syndrome and multiple organ failure. The preparation of CAR-T targeting tumor-specific new antigens can solve the "off-target" problem. Currently, clinical trials of CAR-T targeting new targets of ErbB2, gangliosides, and prostate-specific membrane antigen are also underway.

5. The method for screening tumor neoantigens according to claim 1, characterized in that: The residue replacement of the antigen epitope replaces the residues at the site where the tyrosinase-associated protein 2 antigen epitope located on melanocytes interacts with the HLA-A*0201 molecule. The affinity and stability of the replaced peptide are improved, and its ability to stimulate and activate T cells and kill tumor cells are better than that of the wild-type tyrosinase-associated protein 2 epitope. The study found that the P modification at the third position (p3) of the melanoma-related epitope gp10025-33 directly improves the affinity of the epitope with TCR, and the amino-terminal anchoring site of the antigen peptide binding motif plays a key role in stabilizing the pMHC-I complex. The antigen peptide p2 replaces aspartic acid with tyrosine, or replaces proline / arginine with leucine at the amino terminal to strengthen the conformational stability of the peptide to facilitate MHC binding. The single residue is replaced based on the pi-pi stacking interaction between the residues, especially after p9 is replaced, the immunogenicity of the weak antigen, the binding free energy between the antigen and HLA, and the CTL activation level are improved.

6. The method for screening tumor neoantigens according to claim 1, characterized in that: The tumor antigen screening based on specific reaction CD8+ and CD4+T cells mainly involves transfecting the cDNA library of tumor cells into a cell line expressing MHC-I or MHC-Ⅱ molecules, and then co-culturing with the established CD8+ or CD4+T cell line that specifically reacts to tumor cells, obtaining positive cell clones by detecting cell lysis or cytokine release, and finally amplifying the positive monoclonal cells to obtain DNA, which is further identified after sequencing. Based on this principle, it has been reported that the screening system for MHC-I and MHC-Ⅱ tumor antigens has been reconstructed and achieved good results. A retrovirus cloning system has been established for MHC-I tumor antigens, in which the tumor cell cDNA library is cloned into a human retrovirus vector, co-transfected with a plasmid encoding VSVG protein into a 293GP packaging cell line, the viral supernatant is collected, and then infected with the body's own fibroblasts, and then Then, they were co-cultured with CD8+T cells that have a specific response to tumor cells, and the positive cell clones were determined by detecting the release of T cell factors. The feasibility of this system was demonstrated by the screening and identification of NY-ESO-1 tumor antigens. For the screening of MHC-Ⅱ tumor antigens, according to the processing principle of MHC-I molecules, cDNAs encoding DRα, DRβ, DMα, DMβ and Ii were transferred to 293 cells, and 293IMDR cells were established. This genetically engineered cell has the same ability to process and present antigens as antigen-presenting cells. Then, a tumor cell cDNA fusion library fused with the Ii targeting sequence was constructed. The combined use of this tumor cell cDNA fusion library and 293IMDR cells made the screening of MHC-Ⅱ tumor antigens relatively simple and quick, which was significantly better than other methods. Tumor antigens such as CDC27 and LDFP were obtained using this screening system.

7. The method for screening tumor neoantigens according to claim 1, characterized in that: The immunogenicity of the predicted neoantigen is usually detected by T response. Although the frequency of neoantigen-reactive T cells in peripheral blood is usually lower than that in tumor samples, the neoantigen-specific T cells derived from circulating CD8+ memory T cells of cancer patients or circulating CD8+ naive T cells of healthy volunteers are enriched by in vitro co-culture with homologous DC cells loaded with neoantigens, and their response ability to recognize neoantigens can be detected by conventional experimental methods. The circulating CD8T cells of healthy donors, which are more easily obtained, are co-cultured with homologous DC loaded with neoantigens for two rounds to verify the immunogenicity of the predicted neoantigens. Except for the positive epitope KRAS_G12 V8-16 In addition, it was found that 11 of the 25 predicted antigens could induce co-cultured CTLs to secrete IFN-Y after loading with T2 cells, and the frequency of specific CTLs producing IFN-γ spots that were more than 10 times that of the negative control was between 0.22% and 7.08%. The remaining 14 candidate neoantigens were not found to be immunogenic. It is speculated that this is because only about 1 T cell out of 10E5~10E6 T cells in general lymph nodes is a neoantigen-specific T cell, and the circulating CD8+ memory T cells of healthy donors do not produce neoantigen-reactive T cells. Enriching the circulating CD8+ naive T cells of healthy volunteers before antigen sensitization can increase the possibility of specific T cells encountering D presenting relevant neoantigens. Due to the individual differences in the donor-dependent T cell population and the sufficient diversity of the human TCR library, multiple donors need to be screened to identify the immunogenicity of the candidate neoantigens. The remaining immunogenicity-negative neoantigen peptides may be obtained from the screening of positive CTLs from other healthy volunteers.

Citation Information

Cited By

  • Method for intelligently recognizing T cell antigen at atomic level

    CN119864088A

  • New antigen screening method, equipment and program product

    CN120048333A

  • Neoantigen load calculation method, equipment and program product

    CN120048334A

  • A method, device and program product for calculating neoantigen load

    CN120048334B

  • Method for accurately screening T cell epitopes of varied pathogens based on artificial intelligence

    CN120600110A